(Q48183000)

9 February 2018

title

Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response (English)

1 reference

9 February 2018

1 reference

5

George K Dresser

1 reference

9 February 2018

author name string

Inna Y Gong

1

1 reference

9 February 2018

Natalie Crown

2

1 reference

9 February 2018

Colin M Suen

3

1 reference

9 February 2018

Ute I Schwarz

4

1 reference

9 February 2018

Michael J Knauer

6

1 reference

9 February 2018

Daisuke Sugiyama

7

1 reference

9 February 2018

Marianne K DeGorter

8

1 reference

9 February 2018

Sarah Woolsey

9

1 reference

9 February 2018

Rommel G Tirona

10

1 reference

9 February 2018

Richard B Kim

11

1 reference

9 February 2018

publication date

27 February 2012

1 reference

9 February 2018

published in

European Heart Journal

1 reference

9 February 2018

volume

33

1 reference

9 February 2018

issue

22

1 reference

9 February 2018

page(s)

2856-2464a

1 reference

9 February 2018

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Paraoxonase-1 and clopidogrel efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS042

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHS042

1 reference

9 February 2018

1 reference

9 February 2018